BALTIMORE–(BUSINESS WIRE)–NeoProgen, Inc., a pre-clinical stage company developing an exosome-based product from human neonatal heart-derived Medicinal Signaling Cells (nMSCs) for tissue repair and regeneration for the treatment of heart failure (HF) and other inflammatory diseases, announced that it has received a patent from the United States Patent Office Patent No.: US 10.967,007 B2 “Cardiac Stem Cells for Cardiac Repair”. The innovation was developed by Dr. Sunjay Kaushal, a pediatric cardiac surgeon, while he was at the University of Maryland, Baltimore and NeoProgen is the exclusive licensee of the newly issued patent.
- Maryland Stem Cell Research Commission Announces $4 Million in Grants to Drive Stem Cell Innovations
- Secretome Therapeutics Appoints Margot Connor as Board Director and Assembles World-Class Clinical Advisory Board
- Secretome Therapeutics Appoints Deepa Prasad as Chief Financial Officer
- Neoprogen is now Secretome Therapeutics, in alignment with the company’s focus in revolutionizing cell therapy via neonatal cardiac progenitor cells (nCPCs) and their respective secretomes
- NeoProgen receives approval from U.S. FDA for a Phase I Study of The Safety And Early Efficacy of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) In Chronic Ischemic Heart Failure